Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNASDAQ:KRYSNYSE:OGNNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.67+1.9%$3.70$7.96▼$24.15$13.47M0.6315,376 shs5,727 shsKRYSKrystal Biotech$139.01+1.1%$139.58$122.80▼$219.34$3.97B0.67286,280 shs279,901 shsOGNOrganon & Co.$10.02+3.5%$9.72$8.01▼$23.10$2.52B0.63.51 million shs5.50 million shsVRNAVerona Pharma PLC American Depositary Share$90.48-4.3%$79.65$14.86▼$99.01$8.05B0.241.26 million shs1.83 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+1.91%+13.14%-7.93%-66.63%-84.10%KRYSKrystal Biotech+1.13%-3.24%+9.41%-23.20%-23.73%OGNOrganon & Co.+3.51%+0.76%+8.91%-32.02%-50.62%VRNAVerona Pharma PLC American Depositary Share-4.33%-6.93%+11.94%+50.07%+483.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AKRYSKrystal Biotech4.6257 of 5 stars3.51.00.04.73.12.51.9OGNOrganon & Co.4.8968 of 5 stars3.34.01.73.71.73.32.5VRNAVerona Pharma PLC American Depositary Share2.574 of 5 stars3.51.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AKRYSKrystal Biotech 3.00Buy$211.1351.88% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0079.64% UpsideVRNAVerona Pharma PLC American Depositary Share 3.00Buy$107.3618.66% UpsideCurrent Analyst Ratings BreakdownLatest ALVR, KRYS, VRNA, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025VRNAVerona Pharma PLC American Depositary ShareWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$170.006/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.006/23/2025VRNAVerona Pharma PLC American Depositary SharePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$76.00 ➝ $160.006/20/2025VRNAVerona Pharma PLC American Depositary ShareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$107.00 ➝ $138.006/18/2025VRNAVerona Pharma PLC American Depositary ShareRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.00 ➝ $116.006/11/2025VRNAVerona Pharma PLC American Depositary ShareCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $100.006/11/2025VRNAVerona Pharma PLC American Depositary ShareJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$95.00 ➝ $110.006/2/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$85.00 ➝ $90.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AKRYSKrystal Biotech$290.52M13.83$4.69 per share29.64$32.90 per share4.23OGNOrganon & Co.$6.40B0.41$5.11 per share1.96$1.83 per share5.48VRNAVerona Pharma PLC American Depositary Share$42.28M182.18N/AN/A$2.56 per share35.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1633.4213.79N/A37.17%14.64%13.28%8/4/2025 (Estimated)OGNOrganon & Co.$864M$2.883.482.681.0111.92%227.43%7.34%8/5/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$2.00N/A3,016.00N/AN/A-69.65%-28.00%8/6/2025 (Estimated)Latest ALVR, KRYS, VRNA, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion4/29/2025Q1 2025VRNAVerona Pharma PLC American Depositary Share-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.80%N/A2.78%N/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ALatest ALVR, KRYS, VRNA, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78KRYSKrystal BiotechN/A9.659.27OGNOrganon & Co.16.491.671.15VRNAVerona Pharma PLC American Depositary Share1.078.868.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%KRYSKrystal Biotech86.29%OGNOrganon & Co.77.43%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%KRYSKrystal Biotech13.70%OGNOrganon & Co.1.40%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableOGNOrganon & Co.4,000259.96 million256.32 millionNot OptionableVRNAVerona Pharma PLC American Depositary Share3085.13 million81.05 millionOptionableALVR, KRYS, VRNA, and OGN HeadlinesRecent News About These CompaniesHere's Why Momentum in Verona Pharma (VRNA) Should Keep goingJuly 1 at 9:50 AM | zacks.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Now Covered by Wolfe ResearchJuly 1 at 8:40 AM | marketbeat.comAllspring Global Investments Holdings LLC Takes $33.15 Million Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 1 at 4:48 AM | marketbeat.comSG Americas Securities LLC Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)June 26, 2025 | marketbeat.comHBK Sorce Advisory LLC Sells 3,800 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)June 25, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Reaches New 52-Week High on Analyst UpgradeJune 25, 2025 | americanbankingnews.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High After Analyst UpgradeJune 23, 2025 | marketbeat.comPiper Sandler Forecasts Strong Price Appreciation for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) StockJune 23, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Shares Sold by PFG Investments LLCJune 22, 2025 | marketbeat.comRoth Capital Hikes Verona Pharma’s (VRNA) Price Target to $116 On COPD Market ProspectsJune 20, 2025 | msn.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given New $138.00 Price Target at Wells Fargo & CompanyJune 20, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Andrew Fisher Sells 80,000 Shares of StockJune 19, 2025 | insidertrades.comMission Wealth Management LP Purchases New Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)June 19, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $922,400.00 in StockJune 18, 2025 | marketbeat.comVerona Pharma: An Impressive Initial LaunchJune 18, 2025 | seekingalpha.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Buy" Rating from Roth CapitalJune 18, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Hits New 12-Month High - What's Next?June 16, 2025 | marketbeat.comTraders Purchase High Volume of Verona Pharma Put Options (NASDAQ:VRNA)June 16, 2025 | marketbeat.comJefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre LaunchJune 14, 2025 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in StockJune 14, 2025 | insidertrades.comVerona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in StockJune 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALVR, KRYS, VRNA, and OGN Company DescriptionsAlloVir NASDAQ:ALVR$2.67 +0.05 (+1.91%) As of 06/30/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Krystal Biotech NASDAQ:KRYS$139.01 +1.55 (+1.13%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$144.06 +5.05 (+3.63%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Organon & Co. NYSE:OGN$10.02 +0.34 (+3.51%) Closing price 07/1/2025 03:59 PM EasternExtended Trading$10.05 +0.03 (+0.30%) As of 06:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$90.48 -4.10 (-4.33%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$89.16 -1.32 (-1.45%) As of 06:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
